Clinical Research Directory

Inclusion Criteria: * Age 18-75 years and able to provide written informed consent. * Primary non-squamous NSCLC confirmed by pathology, with no brain metastases. * Complete R0 surgical resection (lobectomy, segmentectomy, or pneumonectomy) of stage IA or IB NSCLC (AJCC 8th edition). * High-risk disease (one or more): low differentiation, solid/micropapillary/complex glandular patterns, vascular invasion, visceral pleural invasion, alveolar space spread, or intermediate/high risk on 14-gene test. * Documented driver gene status (EGFR mutation, ALK/ROS1 fusion, or wild-type) via postoperative tumor sample. * ECOG performance status 0 or 1, with stable condition over the last two weeks. * Surgery within 4-10 weeks before starting treatment, with full recovery. * Adequate organ function as per protocol-defined labs. * Negative pregnancy test (if applicable) and use of effective contraception during and 3 months after treatment. Exclusion Criteria: * Evidence of unresectable/metastatic NSCLC, incomplete resection (R1/R2), or wedge resection only. * Prior systemic therapy (e.g., chemotherapy, targeted therapy, immunotherapy) for the current NSCLC. * Major surgery (excluding lung cancer surgery) within 3 weeks before first study dose. * Planned concurrent anti-cancer therapy (chemo, radiotherapy, or targeted therapy) during the study. * Clinically significant cardiac disorders (e.g., poorly controlled hypertension, recent MI or stroke, prolonged QTc). * History or suspicion of interstitial lung disease requiring treatment. * Active or uncontrolled infection (e.g., hepatitis B with detectable HBV DNA, hepatitis C, HIV, active TB). * Severe GI conditions impairing drug absorption (e.g., Crohn's, ulcerative colitis). * Use of strong CYP3A inducers/inhibitors within 1 week or ongoing need for warfarin. * Participation in another interventional trial within 4 weeks or receipt of a live vaccine within 180 days. * Any condition that may compromise adherence or safety, per investigator judgment.